Latest Amplimmune Inc. Stories

TOKYO and GAITHERSBURG, Maryland, Jan. 7, 2013 /PRNewswire/ -- Daiichi Sankyo, Co., Ltd. (hereafter, Daiichi Sankyo) and Amplimmune, Inc. (hereafter, Amplimmune) announced today that they have entered into a broad strategic collaboration to develop a new therapeutic protein, AMP-110 (B7-H4 fusion protein). The collaboration will focus on development of AMP-110, a potential immune modulation therapy for autoimmune diseases. This proprietary, first-in-class biologic works by blocking...

ROCKVILLE, Md., Aug. 4 /PRNewswire/ -- Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1. Under the terms of this agreement, GSK will pay Amplimmune a non-refundable upfront payment of $23...